Kinarus have announced the signing of an agreement with ChaoDain (Hangzhou) Investment Management (CDIM) for a CHF 1.5m convertible loan that will form the basis for the development of KIN001 in the treatment of idiopathic pulmonary fibrosis (IPF) in China.
This is an important validation of the potential of KIN001 in IPF and could be the first of a sequence of transactions that result in development collaborations on KIN001, and not just in IPF.
We regard the investment by ChaoDain Investm ....
12 May 2023
First transaction on KIN001
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
First transaction on KIN001
Kinarus Therapeutics Holding AG (KNRS:SWX) | 0 0 0.0%
- Published:
12 May 2023 -
Author:
Andy Smith -
Pages:
4
Kinarus have announced the signing of an agreement with ChaoDain (Hangzhou) Investment Management (CDIM) for a CHF 1.5m convertible loan that will form the basis for the development of KIN001 in the treatment of idiopathic pulmonary fibrosis (IPF) in China.
This is an important validation of the potential of KIN001 in IPF and could be the first of a sequence of transactions that result in development collaborations on KIN001, and not just in IPF.
We regard the investment by ChaoDain Investm ....